IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy
This study underscores the role of IP6K2 as potential markers of resistance, which opens avenues for precision medicine approaches in OVT.
Authors
- Yangkun Shen (ORCID: https://orcid.org/0000-0001-5135-427X)
- Hucheng Zhang
- Xiangqian Zhao (ORCID: https://orcid.org/0009-0002-2251-2878)
- Quan Chen (ORCID: https://orcid.org/0000-0001-7539-8728)
- Huang Zhi-jian (ORCID: https://orcid.org/0000-0002-7948-425X)
- Ruirong Tan (ORCID: https://orcid.org/0000-0003-1719-1416)
- Dawei Wang (ORCID: https://orcid.org/0000-0002-1556-1594)
- Zirong Jiang
- Xinhao Sun (ORCID: https://orcid.org/0000-0001-9736-633X)
- Xiaoting Qiu
Institutions
- Fujian Normal University (CN)
- Northeastern University (US)
- Fujian Medical University (CN)
- Beth Israel Deaconess Medical Center (US)
- Ningde Normal University (CN)
- Sichuan Academy of Traditional Chinese Medicine (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1186/s12967-025-06265-0
- Citations
- 2
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- National Natural Science Foundation of China